Vollständiger Abstract
Worum geht es in dieser Arbeit?
Diabetes mellitus continues to impose a substantial global health burden, underscoring the need for therapeutic systems capable of achieving precise, adaptive, and patient-friendly glycemic control. Conventional diabetes treatments, including repeated insulin injections and oral hypoglycemic agents, are often constrained by non-physiological drug release, poor adherence, systemic side effects, and the persistent risk of hypoglycemia. In this context, glucose-responsive nanomedicine has emerged as a promising platform for next-generation diabetes therapy by enabling self-regulated and glucose-triggered delivery of insulin and other antidiabetic agents. This review highlights recent advances in glucose-responsive nanomedicine, focusing on the principal sensing mechanisms, including glucose oxidase-based, phenylboronic acid-based, and lectin-mediated systems, as well as the nanoscale carriers engineered to support them, such as polymeric nanoparticles, nanogels, micelles, liposomes, and hybrid nanostructures. These smart platforms offer significant potential to improve drug stability, enhance targeting efficiency, reduce dosing frequency, and more closely mimic endogenous insulin secretion. The review further examines their emerging role in precision diabetes care, particularly in combination with continuous glucose monitoring technologies, wearable devices, and closed-loop therapeutic systems. Despite notable progress at the preclinical level, important barriers to clinical translation remain, including challenges related to biocompatibility, long-term safety, reproducibility, scalable manufacturing, and regulatory approval. Collectively, glucose-responsive nanomedicine represents a rapidly advancing and clinically relevant field with the potential to redefine diabetes management through intelligent and personalized therapeutic strategies. This review provides a focused overview of current developments, key translational challenges, and future directions toward clinical implementation.
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Adnan Alsaei, Ayah Binrajab, Shahd Alsaei, Fatema Rahimi, Ahmad Zarwi, Helen N. Zarwi, Renad Alansari, G. Roshan Deen
- Quelle
- Journal of Functional Biomaterials
- Publikation
- 2026-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- 2079-4983
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Adnan Alsaei, Ayah Binrajab, Shahd Alsaei, Fatema Rahimi, Ahmad Zarwi, Helen N. Zarwi, Renad Alansari, G. Roshan Deen (2026). Glucose-Responsive Nanomedicine in Diabetes Therapy: Emerging Advances and Clinical Prospects. Journal of Functional Biomaterials. https://doi.org/10.3390/jfb17090424
Kontext
Themen, Förderung und Nutzung
Lizenzhinweise: Lizenz 1